 |
 |
Good grief! I was composing an email and the dog grabbed some papers off the table. During the ensuing chase (slo-mo, of course), my phone's voice-to-text feature recorded my rant at the dog, and I must have pushed "send" by mistake. When I returned to email just now, I saw that what I had expected to expand and edit had been sent "as is." Sheesh. I am mortified, but relieved that my response to Dollydog was G-rated, albeit jumbled. Dolly really is, by the way, a very good dog with an unfortunate taste for paper products. The point I was trying to get to in the truncated email was that there seem to be a fair number of people and corporate entities that have—or potentially have, or would like to have—a financial interest in the success of this drug.To the extent that this pushes the research, it should be a good thing. But when a lot of money is at stake, things get messy. So we have to be vigilant. Just saying. Kathleen On 6 November 2015 at 12:30, Kathleen Cochran <[log in to unmask]> wrote: > I don't see evidence of a "you miserable wretch 11 on you let's go you're > a bad dog media blitz" regarding Nilotinib. If anything, the media appears > to me to be remarkably quiet, considering the potential of this > development. But > I > This article says next to nothing about the Georgetown team and quite a > lot about the Dawsons. > > Another article out of Georgetown mentions that Dr. Moussa, the Georgetown > principal investigator,is applying for a patent related to his study. Then > there is Dr. Drucker, and of course Novartis…plenty here for quite a stew. > > On Friday, November 6, 2015, Nic Marais <[log in to unmask]> wrote: > >> A very informative and sobering article... >> I >> Nic 63/21 >> >> On 5 November 2015 at 22:00, Rayilyn Brown <[log in to unmask]> wrote: >> >> > http://www.parkinson.org/find-help/blogs/what-s-hot >> > Ray >> > Rayilyn Brown >> > Past Director AZNPF >> > Arizona Chapter National Parkinson Foundation >> > >> > ---------------------------------------------------------------------- >> > To sign-off Parkinsn send a message to: mailto: >> > [log in to unmask] >> > In the body of the message put: signoff parkinsn >> > >> >> ---------------------------------------------------------------------- >> To sign-off Parkinsn send a message to: mailto: >> [log in to unmask] >> In the body of the message put: signoff parkinsn >> > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn